

Press release Montpellier (France), July 16, 2018 - 5:45 pm CEST

# Intrasense unveils the latest version of Myrian<sup>®</sup> at CHIMA Chinese tradeshow

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces the worldwide launching of the latest version of Myrian<sup>®</sup> during the hospital information systems tradeshow (<u>CHIMA</u>), held from July 12 to 15 2018 in Guiyang (China).

Myrian<sup>®</sup> 2.4 includes new exclusive diagnosis tools, for breast and colon in particular. Now available on a full-web mode, these tools are seamless integrable within any health information system.

## Enriched clinical features, new algorithms

A new application dedicated to colon enables more effective virtual coloscopies: based on unique image processing technologies developed by Intrasense, such as 3D image registration and segmentation, it also includes a « bowel-cleansing » feature, optimizing reading.

A new « breast MRI » characterization algorithm for lesions makes malignant tumors diagnosis much more reliable, to avoid « false-positive » results.

« This year, Myrian<sup>®</sup> is enriched of exclusive new clinical features, making diagnosis more reliable and still optimizing time for analysis. » comments Philippe Michelon, Product Director at Intrasense. « With « Quick Patient » functions, essential assistance tools to diagnosis are always within reach for practitioner, in the natural workflow of exam reading. »

## Myrian<sup>®</sup> available on full-web mode for large-scale deployment

Partnerships concluded in early 2018 with 12 Sigma Technologies, MinFound or Evolucare, have allowed to perfect integration and deployment capabilities of <u>Myrian® Imaging Layer</u> offer within any health system.

« This new version makes easier large-scale deployment of all Myrian<sup>®</sup> tools for image interpretation: they are now available on full-web mode, enabling addressing new business cases, required for Myrian<sup>®</sup> Imaging Layer deployment on large-scale organizations. » concludes Philippe Michelon.

The CHIMA tradeshow will have been the occasion of Myrian<sup>®</sup> 2.4 launching in China, a <u>huge potential market</u>, and to meet Chinese actors of health systems with <u>Evolucare</u>, the brand new French partner of Intrasense.



#### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian<sup>®</sup>, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian<sup>®</sup>, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian<sup>®</sup> also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

More information on <u>www.intrasense.fr</u>.

### Contacts

Intrasense Nicolas Reymond Chief Executive Officer Montpellier - FRANCE Tel: +334 67 130 130 investor@intrasense.fr

ALINS EURONEXT GROWTH NewCap Investor Relations and Financial Communication Valentine Brouchot - Pierre Laurent Tel: +331 44 71 94 96 intrasense@newcap.eu